Multistate Illegal Marketing Settlement
GlaxoSmithKline agreed to pay a total of $105 million to 44 states and the District of Columbia to settle allegations that the company unlawfully promoted its asthma drug, Advair, and antidepressant drugs Paxil and Wellbutrin. Glaxo was accused by the states of illegally marketing Advair for use by mild asthma sufferers, and Paxil and Wellbutrin for use by children and teenagers without approval by the Food and Drug Administration (FDA). Under the agreement, Glaxo, which did not admit any liability or wrongdoing, agreed to cease paying health care providers to promote its products and giving sales representatives incentives to promote its drugs for unapproved uses. The agreement also bans Glaxo from disseminating information describing any off-label use of a product, unless such information and materials are consistent with applicable FDA regulations and guidance.
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Settlement Announcement